Alios BioPharma Garners $8,400,000 Series A Financing
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=7a993878-260f-4a78-b278-251349bd3046&Preview=1 -
Date
2/9/2009 -
Company Name
Alios BioPharma -
Mailing Address
101 A Hickey Boulevard South San Francisco, CA 94080 -
Company Description
Alios is discovering and developing novel therapeutic agents based on three platform technologies including: small molecule activators of innate immunity antiviral pathways (RNase L activation), phosphate protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons (Glycoferonâ). This complementary group of platform technologies has the potential to generate a number of distinct therapeutic products to treat a variety of serious viral infections such as chronic hepatitis B and C, HIV infection, and respiratory viruses (e.g. pandemic influenza) and emerging viral diseases (e.g. SARS). -
Website
http://www.aliosbiopharma.com -
Transaction Type
Venture Equity -
Transaction Amount
$8,400,000 -
Transaction Round
Series A -
Proceeds Purposes
Proceeds purposes were not disclosed. -
M&A Terms
-
Venture Investor
Novo A/S -
Venture Investor
Novartis BioVenture Fund -
Venture Investor
Roche Venture Fund
